A Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Alone or in Combination With a Sulphonylurea

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 678 participants.

Also called NCT01381900

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 678 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01381900
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
China, Malaysia, Vietnam (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01381900. Randomized; double masking; primary purpose treatment. Start 2011-08 (registry gives no type); primary completion 2012-11 (actual). Results posted on 2014-01-09.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Alone or in Combination With a Sulphonylurea
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Placebo
Intervention (Drug)
Canagliflozin 100mg
Intervention (Drug)
Canagliflozin 300mg
Intervention (Drug)
Metformin
Intervention (Drug)
Sulphonylurea
Lead sponsor
Janssen Research & Development, LLC (class: industry)

Record details

Record id
cardio:ct-nct01381900
Content hash
77edd8eefb6bc5b950a877de5a0e41b903d440e3805cbf21071125ae3e059eb8